Eagle Global Advisors LLC Decreases Position in Celgene Corporation (NASDAQ:CELG)

Eagle Global Advisors LLC lowered its position in shares of Celgene Corporation (NASDAQ:CELG) by 1.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 100,460 shares of the biopharmaceutical company’s stock after selling 1,030 shares during the period. Eagle Global Advisors LLC’s holdings in Celgene Corporation were worth $12,500,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of CELG. Sowell Financial Services LLC purchased a new stake in Celgene Corporation during the fourth quarter worth approximately $294,000. Assenagon Asset Management S.A. purchased a new stake in Celgene Corporation during the fourth quarter worth approximately $18,929,000. Numeric Investors LLC purchased a new stake in Celgene Corporation during the fourth quarter worth approximately $5,718,000. Advantage Investment Management LLC purchased a new stake in Celgene Corporation during the fourth quarter worth approximately $154,000. Finally, Thrivent Financial for Lutherans boosted its stake in Celgene Corporation by 11.1% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,526,850 shares of the biopharmaceutical company’s stock worth $176,756,000 after buying an additional 152,924 shares during the period. Institutional investors own 78.34% of the company’s stock.

Shares of Celgene Corporation (CELG) opened at 127.65 on Friday. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00. The stock has a 50 day moving average price of $133.74 and a 200 day moving average price of $124.92. The stock has a market capitalization of $99.87 billion, a P/E ratio of 39.53 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.21. The company had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.44 earnings per share. Equities analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.com-unik.info/2017/08/19/eagle-global-advisors-llc-sells-1030-shares-of-celgene-corporation-nasdaqcelg-updated-updated.html.

A number of analysts recently commented on the company. Mizuho set a $134.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research report on Wednesday, July 26th. Cantor Fitzgerald set a $160.00 price target on Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 27th. Robert W. Baird reissued an “outperform” rating and set a $162.00 price target on shares of Celgene Corporation in a report on Friday, July 21st. Jefferies Group LLC reissued a “buy” rating and set a $160.00 price target on shares of Celgene Corporation in a report on Monday, July 31st. Finally, Cann reissued a “buy” rating and set a $175.00 price target on shares of Celgene Corporation in a report on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $147.00.

In other Celgene Corporation news, Director Ernest Mario sold 18,506 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the sale, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Rupert Vessey sold 4,785 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the sale, the insider now directly owns 4,004 shares in the company, valued at approximately $481,200.72. The disclosure for this sale can be found here. In the last three months, insiders sold 253,761 shares of company stock worth $33,792,445. 0.95% of the stock is owned by corporate insiders.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit